Hubei Noon Pharmaceutical Research Institute Co., Ltd.

Primary study objectives: To evaluate the bioequivalence of the test preparation hydroxychloroquine sulfate tablets (provided by Hubei Wushi Pharmaceutical Research Institute Co., Ltd.) 0.2g and the reference preparation hydroxychloroquine sulfate tablets (Plaquenil®, produced by Sanofi-Aventis SA) 0.2g in healthy Chinese subjects under fasting and postprandial administration conditions. Secondary study objectives: To observe the safety of the test preparation and the reference preparation in healthy subjects.

A bioequivalence study was conducted in healthy subjects with a single oral dose of sitagliptin metformin tablets (II) (test preparation T, produced by Hubei Wushi Pharmaceutical Research Institute Co., Ltd., specifications: 50 mg/850 mg/tablet) and sitagliptin metformin tablets (II) (reference preparation R, produced by MSD Pharma (Singapore) Pte. Ltd., trade name: JANUVIA®/Janoda®, specifications: 50 mg/850 mg/tablet) under fasting/fed conditions to investigate the absorption rate and extent of sitagliptin metformin tablets (II) under fasting and fed conditions and to evaluate whether the test preparation and the reference preparation are bioequivalent.

Primary objective: To evaluate the pharmacokinetic characteristics of the test formulation of phloroglucinol oral lyophilized tablets (specification: 80 mg, holder: Hubei Wushi Pharmaceutical Research Institute Co., Ltd.) and the reference formulation (trade name: Spasfon-lyoc®, specification: 80 mg, holder: Teva Sante) after a single oral administration under fed conditions in healthy Chinese subjects, and to investigate whether the two are bioequivalent under fed conditions. Secondary objective: To evaluate the safety of the test formulation of phloroglucinol oral lyophilized tablets (specification: 80 mg) and the reference formulation (trade name: Spasfon-lyoc®, specification: 80 mg) in healthy subjects.